MiNK Therapeutics, Inc.INKTEarnings & Financial Report
MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative invariant natural killer T (iNKT) cell therapies to treat cancer, autoimmune disorders and other serious unmet medical needs. It targets the global biopharmaceutical market, with core segments covering oncology and immunology, advancing its allogeneic cell therapy pipeline through preclinical and clinical trials.
INKT Q4 FY2025 Key Financial Metrics
Revenue
$111.2K
Gross Profit
N/A
Operating Profit
$-2.7M
Net Profit
$-2.6M
Gross Margin
N/A
Operating Margin
-2432.3%
Net Margin
-2339.4%
YoY Growth
181.1%
EPS
$-0.52
MiNK Therapeutics, Inc. Q4 FY2025 Financial Summary
MiNK Therapeutics, Inc. reported revenue of $111.2K (up 181.1% YoY) for Q4 FY2025, with a net profit of $-2.6M (down 5.6% YoY) (-2339.4% margin).
Key Financial Metrics
| Total Revenue | $111.2K |
|---|---|
| Net Profit | $-2.6M |
| Gross Margin | N/A |
| Operating Margin | -2432.3% |
| Report Period | Q4 FY2025 |
MiNK Therapeutics, Inc. Annual Revenue by Year
MiNK Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $463.3K).
MiNK Therapeutics, Inc. Quarterly Revenue & Net Profit History
MiNK Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $111.2K | +181.1% | $-2.6M | -2339.4% |
| Q3 FY2025 | $55.2K | -29.3% | $-2.9M | -5236.0% |
| Q4 FY2024 | $39.6K | -4.7% | $-2.5M | -6224.0% |
| Q3 FY2024 | $78.0K | -27.3% | $-1.8M | -2315.7% |
| Q2 FY2024 | $38.4K | -73.8% | $-2.7M | -7043.3% |
| Q4 FY2023 | $41.5K | -69.2% | $-5.5M | -13145.3% |
| Q3 FY2023 | $107.3K | +15.4% | $-5.1M | -4768.8% |
| Q2 FY2023 | $146.4K | +455.0% | $-6.2M | -4233.2% |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $146389 | $107287 | $41525 | $38360 | $78015 | $39574 | $55151 | $111230 |
| YoY Growth | 455.0% | 15.4% | -69.2% | -73.8% | -27.3% | -4.7% | -29.3% | 181.1% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $12.1M | $7.5M | $4.6M | $10.3M | $7.4M | $5.7M | $15.0M | $14.2M |
| Liabilities | $21.6M | $21.0M | $22.6M | $26.9M | $24.9M | $25.3M | $28.5M | $28.5M |
| Equity | $-9.5M | $-13.6M | $-18.1M | $-16.6M | $-17.6M | $-19.6M | $-13.5M | $-14.2M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.2M | $-4.2M | $-3.0M | $-2.3M | $-3.0M | $-1.7M | $-941348 | $-2.1M |